SI3445767T1 - Makrociklični inhibitorji MCL1 za zdravljenje raka - Google Patents
Makrociklični inhibitorji MCL1 za zdravljenje rakaInfo
- Publication number
- SI3445767T1 SI3445767T1 SI201730246T SI201730246T SI3445767T1 SI 3445767 T1 SI3445767 T1 SI 3445767T1 SI 201730246 T SI201730246 T SI 201730246T SI 201730246 T SI201730246 T SI 201730246T SI 3445767 T1 SI3445767 T1 SI 3445767T1
- Authority
- SI
- Slovenia
- Prior art keywords
- macrocyclic
- treating cancer
- mcl1 inhibitors
- mcl1
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326156P | 2016-04-22 | 2016-04-22 | |
| EP17720720.6A EP3445767B1 (en) | 2016-04-22 | 2017-04-21 | Macrocyclic mcl1 inhibitors for treating cancer |
| PCT/EP2017/059511 WO2017182625A1 (en) | 2016-04-22 | 2017-04-21 | Macrocyclic mcl1 inhibitors for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3445767T1 true SI3445767T1 (sl) | 2020-07-31 |
Family
ID=58664658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201730246T SI3445767T1 (sl) | 2016-04-22 | 2017-04-21 | Makrociklični inhibitorji MCL1 za zdravljenje raka |
Country Status (38)
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018009408A (es) | 2016-02-04 | 2018-11-09 | Univ Johns Hopkins | Rapaglutinas, nuevos inhibidores de transportadores de glucosa (glut) y uso de los mismos. |
| US11066416B2 (en) | 2016-02-04 | 2021-07-20 | The Johns Hopkins University | Rapafucin derivative compounds and methods of use thereof |
| US10774110B2 (en) | 2016-02-04 | 2020-09-15 | The Johns Hopkins University | Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof |
| DK3445767T3 (da) | 2016-04-22 | 2020-05-18 | Astrazeneca Ab | Makrocykliske mcl1-inhibitorer til behandling af cancer |
| CN109715632B (zh) | 2016-05-19 | 2021-10-26 | 拜尔公开股份有限公司 | 大环吲哚衍生物 |
| TW201904976A (zh) * | 2017-03-31 | 2019-02-01 | 瑞典商阿斯特捷利康公司 | Ｍｃｌ-１抑制劑及其使用方法 |
| TWI781996B (zh) * | 2017-03-31 | 2022-11-01 | 瑞典商阿斯特捷利康公司 | 合成ｍｃｌ-１抑制劑之方法 |
| AU2018317828A1 (en) * | 2017-08-15 | 2020-04-02 | AbbVie Deutschland GmbH & Co. KG | Macrocyclic MCL-1 inhibitors and methods of use |
| JP2020531433A (ja) | 2017-08-15 | 2020-11-05 | アッヴィ・インコーポレイテッド | 大環状ｍｃｌ−１阻害剤及び使用の方法 |
| AR113886A1 (es) | 2017-11-17 | 2020-06-24 | Broad Inst Inc | Derivados de indol macrocíclicos |
| US11447504B2 (en) | 2017-11-17 | 2022-09-20 | Bayer Aktiengesellschaft | Macrocyclic chlorine substituted indole derivatives |
| EP3710447A1 (en) * | 2017-11-17 | 2020-09-23 | Bayer Aktiengesellschaft | Aryl annulated macrocyclic indole derivatives |
| TWI810220B (zh) * | 2017-11-17 | 2023-08-01 | 德商拜耳廠股份有限公司 | 經取代之巨環吲哚衍生物 |
| TW201932469A (zh) | 2017-11-17 | 2019-08-16 | 德商拜耳廠股份有限公司 | 經巨環氯取代之吲哚衍生物 |
| EP3710449B1 (en) | 2017-11-17 | 2022-07-06 | The Broad Institute, Inc. | Macrocyclic fluorine substituted indole derivatives as mcl-1 inhibitors, for use in the treatment of cancer |
| TW202014184A (zh) * | 2018-04-30 | 2020-04-16 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合 |
| CA3113917A1 (en) * | 2018-09-30 | 2020-04-02 | Jiangsu Hengrui Medicine Co., Ltd. | Indole macrocyclic derivative, preparation method therefor and application thereof in medicine |
| TWI810397B (zh) | 2018-11-14 | 2023-08-01 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| CN111205309B (zh) * | 2018-11-21 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 吲哚类大环衍生物、其制备方法及其在医药上的应用 |
| EP3781570A4 (en) * | 2018-11-22 | 2021-06-02 | Ascentage Pharma (Suzhou) Co., Ltd. | MACROCYCLIC INDOLES SERVING AS MCL-1 INHIBITORS |
| US12319703B2 (en) | 2019-01-23 | 2025-06-03 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic fused pyrazoles as Mcl-1 inhibitors |
| WO2020185606A1 (en) * | 2019-03-08 | 2020-09-17 | Zeno Management, Inc. | Macrocyclic compounds |
| CN113574058B (zh) * | 2019-04-30 | 2024-04-16 | 江苏恒瑞医药股份有限公司 | 吲哚类大环衍生物、其制备方法及其在医药上的应用 |
| MX2021013667A (es) | 2019-05-10 | 2022-01-31 | Janssen Biotech Inc | Quelantes macrocíclicos y métodos de uso de estos. |
| CN114127079A (zh) | 2019-05-17 | 2022-03-01 | 布罗德研究所有限公司 | 制备大环吲哚的方法 |
| AU2020279230A1 (en) | 2019-05-20 | 2021-12-02 | Les Laboratoires Servier | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| KR20220024694A (ko) * | 2019-06-21 | 2022-03-03 | 얀센 파마슈티카 엔.브이. | Mcl-1의 거대환식 억제제 |
| ES2987630T3 (es) | 2019-07-09 | 2024-11-15 | Janssen Pharmaceutica Nv | Derivados de espirociclos macrocíclicos como inhibidores de MCL-1 |
| WO2021067405A1 (en) * | 2019-10-01 | 2021-04-08 | The Johns Hopkins University | Neuroprotective compounds and methods of use thereof |
| WO2021092053A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| WO2021092061A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Combination treatment for senescence-associated diseases |
| WO2021099579A1 (en) | 2019-11-21 | 2021-05-27 | Janssen Pharmaceutica Nv | Macrocyclic indole derivatives as mcl-1 inhibitors |
| WO2021099580A1 (en) | 2019-11-21 | 2021-05-27 | Janssen Pharmaceutica Nv | Macrocyclic sulfonyl derivatives as mcl-1 inhibitors |
| CN115052880A (zh) * | 2019-12-18 | 2022-09-13 | 芝诺管理公司 | 大环化合物 |
| JP2023514364A (ja) * | 2020-02-21 | 2023-04-05 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１の阻害剤としての大環状インドール誘導体 |
| CN115335384B (zh) * | 2020-03-30 | 2024-10-22 | 江苏恒瑞医药股份有限公司 | 一种吲哚类大环衍生物的结晶形式及其制备方法 |
| KR20230017823A (ko) | 2020-05-29 | 2023-02-06 | 얀센 파마슈티카 엔.브이. | Mcl-1의 억제제로서의 마크로사이클릭 7-피라졸-5-일-인돌 유도체 |
| MX2022016004A (es) | 2020-06-19 | 2023-04-11 | Janssen Pharmaceutica Nv | Desderivados de 7-(pirazol-5-il)-indol macrociclicos enlazados a n como inhibidores de mcl-1. |
| CA3181816A1 (en) | 2020-06-19 | 2021-12-23 | Aldo Peschiulli | N-linked macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1 |
| WO2022008674A1 (en) | 2020-07-08 | 2022-01-13 | Janssen Pharmaceutica Nv | Macrocyclic ether containing indole derivatives as inhibitors of mcl-1 |
| WO2022032284A1 (en) * | 2020-08-07 | 2022-02-10 | Zeno Management, Inc. | Macrocyclic compounds |
| EP4251208A1 (en) | 2020-11-24 | 2023-10-04 | Novartis AG | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| EP4008324A1 (en) | 2020-12-07 | 2022-06-08 | Cellestia Biotech AG | Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer |
| JP2023553719A (ja) | 2020-12-17 | 2023-12-25 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１阻害剤としての分岐大環状４－（ピラゾール－５－イル）－インドール誘導体 |
| CN116848126A (zh) | 2021-02-12 | 2023-10-03 | 詹森药业有限公司 | 大环1,3-桥联的6-氯-7-吡唑-4-基-1h-吲哚-2-羧酸酯和6-氯-7-嘧啶-5-基-1h-吲哚-2-羧酸酯衍生物作为mcl-1抑制剂用于治疗癌症 |
| WO2022251247A1 (en) * | 2021-05-28 | 2022-12-01 | Zeno Management, Inc. | Macrocyclic compounds |
| KR20240019330A (ko) | 2021-06-11 | 2024-02-14 | 길리애드 사이언시즈, 인코포레이티드 | Mcl-1 저해제와 항체 약물 접합체의 조합 |
| US11957693B2 (en) | 2021-06-11 | 2024-04-16 | Gilead Sciences, Inc. | Combination MCL-1 inhibitors with anti-cancer agents |
| CN115490708B (zh) * | 2021-06-18 | 2025-01-24 | 苏州亚盛药业有限公司 | 磺酰胺类大环衍生物及其制备方法和用途 |
| WO2023057484A1 (en) | 2021-10-06 | 2023-04-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy |
| KR20250027285A (ko) | 2022-05-20 | 2025-02-25 | 노파르티스 아게 | 항신생물 화합물의 항체-약물 접합체 및 그의 사용 방법 |
| WO2025111431A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd7 antibody-drug conjugates and methods of use thereof |
| WO2025111450A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd74 antibody-drug conjugates and methods of use thereof |
| WO2025126157A1 (en) | 2023-12-15 | 2025-06-19 | Advesya | Anti-il-1rap binding domains and antibody-drug conjugates thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2134685T3 (en) | 2007-04-16 | 2015-12-07 | Abbvie Inc | 7-unsubstituted indole derivatives as MCL-1 inhibitors |
| NZ579833A (en) | 2007-04-16 | 2012-11-30 | Abbott Lab | 7-substituted indole mcl-1 inhibitors |
| JP5670914B2 (ja) * | 2008-12-22 | 2015-02-18 | キュービスト ファーマシューティカルズ， インコーポレイテッド | グラム陽性菌感染症を処置するための新規抗菌剤 |
| EA201200855A1 (ru) * | 2009-12-23 | 2013-04-30 | Айронвуд Фармасьютикелз, Инк. | Модуляторы crth2 |
| HRP20220319T1 (hr) * | 2011-05-19 | 2022-05-13 | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Makrociklički spojevi kao inhibitori protein kinaze |
| WO2014047427A2 (en) | 2012-09-21 | 2014-03-27 | Vanderbilt University | Substituted benzofuran, benzothiophene and indole mcl-1 inhibitors |
| EP3038618B1 (en) | 2013-08-28 | 2020-10-14 | Vanderbilt University | Substituted indole mcl-1 inhibitors |
| ES2654242T3 (es) * | 2014-02-12 | 2018-02-12 | Viiv Healthcare (No.5) Limited | Macrociclos de benzotiazol como inhibidores de la réplica del virus de la inmunodeficiencia humana |
| US10533010B2 (en) | 2014-03-27 | 2020-01-14 | Vanderbilt University | Substituted indole Mcl-1 inhibitors |
| CR20160471A (es) * | 2014-04-11 | 2016-12-21 | Bayer Pharma AG | Compuestos novedosos macrocíclicos |
| US9949965B2 (en) | 2014-10-17 | 2018-04-24 | Vanderbilt University | Tricyclic indole Mcl-1 inhibitors and uses thereof |
| DK3445767T3 (da) | 2016-04-22 | 2020-05-18 | Astrazeneca Ab | Makrocykliske mcl1-inhibitorer til behandling af cancer |
-
2017
- 2017-04-21 DK DK17720720.6T patent/DK3445767T3/da active
- 2017-04-21 KR KR1020187033540A patent/KR102388208B1/ko active Active
- 2017-04-21 TN TNP/2018/000319A patent/TN2018000319A1/en unknown
- 2017-04-21 HR HRP20200673TT patent/HRP20200673T1/hr unknown
- 2017-04-21 MX MX2018012711A patent/MX386103B/es unknown
- 2017-04-21 ES ES17720720T patent/ES2791319T3/es active Active
- 2017-04-21 WO PCT/EP2017/059511 patent/WO2017182625A1/en not_active Ceased
- 2017-04-21 MA MA44721A patent/MA44721B1/fr unknown
- 2017-04-21 AR ARP170101026A patent/AR108301A1/es active IP Right Grant
- 2017-04-21 PE PE2018001558A patent/PE20181803A1/es unknown
- 2017-04-21 RS RS20200549A patent/RS60257B1/sr unknown
- 2017-04-21 US US15/493,210 patent/US9840518B2/en active Active
- 2017-04-21 PL PL17720720T patent/PL3445767T3/pl unknown
- 2017-04-21 HU HUE17720720A patent/HUE049591T2/hu unknown
- 2017-04-21 LT LTEP17720720.6T patent/LT3445767T/lt unknown
- 2017-04-21 CO CONC2018/0008759A patent/CO2018008759A2/es unknown
- 2017-04-21 TW TW106113380A patent/TWI742074B/zh active
- 2017-04-21 PT PT177207206T patent/PT3445767T/pt unknown
- 2017-04-21 SM SM20200249T patent/SMT202000249T1/it unknown
- 2017-04-21 SI SI201730246T patent/SI3445767T1/sl unknown
- 2017-04-21 CR CR20180499A patent/CR20180499A/es unknown
- 2017-04-21 ME MEP-2020-99A patent/ME03729B/me unknown
- 2017-04-21 JP JP2018553226A patent/JP6894449B2/ja active Active
- 2017-04-21 CN CN201780022366.0A patent/CN109071566B/zh active Active
- 2017-04-21 EP EP17720720.6A patent/EP3445767B1/en active Active
- 2017-04-21 EA EA201892300A patent/EA036551B1/ru not_active IP Right Cessation
- 2017-04-21 CA CA3020378A patent/CA3020378A1/en active Pending
- 2017-04-21 AU AU2017252222A patent/AU2017252222B2/en active Active
- 2017-04-21 SG SG11201805838UA patent/SG11201805838UA/en unknown
- 2017-04-21 BR BR112018070677-9A patent/BR112018070677B1/pt active IP Right Grant
- 2017-10-23 US US15/790,660 patent/US10196404B2/en active Active
-
2018
- 2018-08-23 CL CL2018002410A patent/CL2018002410A1/es unknown
- 2018-09-12 SV SV2018005742A patent/SV2018005742A/es unknown
- 2018-09-25 NI NI201800093A patent/NI201800093A/es unknown
- 2018-10-05 DO DO2018000222A patent/DOP2018000222A/es unknown
- 2018-10-09 IL IL262237A patent/IL262237B/en unknown
- 2018-10-18 PH PH12018502227A patent/PH12018502227A1/en unknown
- 2018-11-19 ZA ZA2018/07766A patent/ZA201807766B/en unknown
- 2018-12-18 US US16/223,538 patent/US10889594B2/en active Active
-
2020
- 2020-05-14 CY CY20201100443T patent/CY1123186T1/el unknown
- 2020-12-04 US US17/111,896 patent/US11472816B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201807766B (en) | Macrocyclic mcl1 inhibitors for treating cancer | |
| IL298497B1 (en) | A method for treating cancer | |
| IL323396A (en) | Cancer treatment methods | |
| IL289947A (en) | A method for treating cancer | |
| IL252610A0 (en) | Methods and preparations for the treatment of cancer | |
| SG11201708861VA (en) | Methods for treating cancer | |
| IL257691A (en) | A method for treating cancer | |
| EP3177292A4 (en) | Compounds and methods for treating cancer | |
| IL249231A0 (en) | Pharmaceutical combinations for cancer treatment | |
| IL256836B (en) | Methods for treating cancer using apilimod | |
| IL255022A0 (en) | Cancer treatment methods | |
| ZA201900052B (en) | Pharmaceutical combinations for treating cancer | |
| IL246558A0 (en) | New methods of cancer treatment | |
| IL255018A0 (en) | Cancer treatment methods | |
| IL255016A0 (en) | Cancer treatment methods | |
| EP3303289A4 (en) | Compounds and methods for treating cancer | |
| SG10201508795XA (en) | Method for treating cancer | |
| IL265537A (en) | Methods of treating ovarian cancer | |
| AU2014904697A0 (en) | Compounds for treating cancer |